Treace Medical Concepts (TMCI) Research & Development (2020 - 2026)

Treace Medical Concepts (TMCI) has reported Research & Development for 7 consecutive years, with $30.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 6.48% year-over-year to $30.9 million; the trailing twelve-month figure through Jun 2026 stood at $136.4 million (down 1.77% YoY), and the FY2025 full-year result was $140.9 million, down 4.58% from the prior year.
• Research & Development slipped to $30.9 million in Q2 2026 per TMCI's latest filing, from $33.8 million in the prior quarter.
• Across five years, Research & Development topped out at $40.3 million in Q1 2024 and bottomed at $22.3 million in Q1 2022.
• Historically, Research & Development has averaged $33.3 million across 5 years, with a median of $33.7 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Research & Development surged 89.94% in 2022, then fell 12.2% in 2025.
• Over 5 years, Research & Development stood at $30.1 million in 2022, then soared by 32.68% to $39.9 million in 2023, then dropped by 7.68% to $36.9 million in 2024, then gained by 1.07% to $37.3 million in 2025, then dropped by 16.95% to $30.9 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $30.9 million, $33.8 million, and $37.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.